fbpx
    • Multiple Myeloma News
    • Oct 31, 2019

    First Patient Dosed with Off-The-Shelf Donor CAR T Cell Therapy Targeting CS1

image_print

A new CAR T treatment has been delivered to the first myeloma patient, using an off-the-shelf approach with donor T cells aimed at a new target, CS1.

Most CAR T cell therapies in today’s multiple myeloma clinical trials are “autologous,” meaning they use the patient’s own T cells. Many CAR T cell therapies in Phase I or II clinical trials are also targeting BCMA.

In the new MELANI-01 trial, open at MD Anderson Cancer Center, an off-the-shelf CAR T treatment is being used. This means that the T cells were obtained from a donor and the treatment is developed in advance. There is no need to wait for CAR T production as with the autologous versions. The treatment is called UCARTCS1 and the Phase I is a dose-escalation study to test the safety, expansion and persistence of the therapy. 

“This first patient dosing for our MELANI-01 clinical trial is an important advancement, as our team has worked tirelessly to develop and take the CS1 target from the lab to the clinic,” said Dr. André Choulika, Chairman and CEO, Cellectis. “In taking this next clinical step, we look forward to deepening our understanding of UCARTCS1 as a potential new treatment option for relapsed/refractory multiple myeloma patients in the future.”

Dr. Krina Patel at MD Anderson Cancer Center is leading the trial. The study is also open at Hackensack and will be open at Weill Cornell Medicine in the future.

It will be fascinating to learn how this compares to the current BCMA CAR T therapies and if they could potentially be used in combination in the future. 

To learn more about this study, click here. 

 

About Author

Jenny A

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical trials. Founder of Myeloma Crowd, Myeloma Crowd Radio and the CrowdCare Foundation.

7 Comments

  1. Randy Morgan November 1, 2019 at 2:36 pm

    Why isn’t Crowd Care Foundation mentioned among the 1M+ non-profits that Guide Star covers? I do see that the Fidelity Charitable Gift Fund has your organization in its list.

    • Allyse Shumway November 5, 2019 at 11:59 am

      Hi Randy – thank you for reaching out! We are registered under GuideStar under “CrowdCare Foundation”, here is a link to our profile – https://www.guidestar.org/profile/45-5354811. Double-check that CrowdCare is one word too, sometimes that may be the mistake. Let me know if you still can’t find it and I’ll reach out to GuideStar. Best wishes, Allyse

  2. George Srnone November 1, 2019 at 9:07 pm

    I am a multiple myeloma patient in remission I have had a SCT and have been on maintenance therapy for several years

  3. Sharon Oneal November 2, 2019 at 3:40 am

    Jenny, thank thank you for doing what you do my wife had her stem cell transplant in March of 2016 she is still in remission thank thank God love the new technology and research that MD Anderson is doing I pray that this new treatment will be a great success towards wiping out mm totally God bless you Jeannie

  4. Cheryl McCullough November 11, 2019 at 2:41 pm

    Had sct in Aug 2017 relasp in April 2019 doing chemo my numbers went up so they are going to do chemo again and add a pill 3 weeks on week. Indiana don’t have good myeloma doctors ask him about c clinical trial they don’t have anything wants me to do another sct using a the doner this time.Dont know about that if not he gives me two years and said it will be hell

    • Jenny A
      Jenny A November 12, 2019 at 2:40 pm

      Cheryl, if you have high risk myeloma then allogeneic (donor) transplant may not be that effective. Usually it is used for young, newly diagnosed high risk myeloma patients. There are good myeloma docs in Indiana and I would HIGHLY suggest that you get a second opinion. Here’s a wonderful specialist. https://medicine.iu.edu/faculty/4996/abonour-rafat/

  5. Tonya Hillenbrand November 12, 2019 at 3:35 pm

    This is awesome ! Hoping all goes well with patient #1

Leave A Comment

Please enter the correct captcha code to verify that you are human.

MYELOMA CROWD RESEARCH INITIATIVE
$167301 of $500,000 Raised
BRINGING THE RIGHT TREATMENT TO THE PATIENT AT THE RIGHT TIME
Please Help Us Reach Our Goal

AmazonSmile

Get Started Today.

Find a Clinical Trial that's Right for You

Go

Thanks to our site sponsors: